PHILADELPHIA–(BUSINESS WIRE)–Integral Molecular, a leader in membrane protein antibody discovery, announces the issuance of a new patent and patent family protecting the composition of matter for its Lipoparticle technology. Lipoparticles represent a proprietary Integral Molecular technology that feature highly-concentrated membrane proteins in their native conformation for drug and antibody discovery against high-value targets including G protein-coupled receptors (GPCRs), ion channels, and transporters. This represents the third issued patent family surrounding the Lipoparticle technology.
US Patent No. 8,574,590 was granted by the USPTO on November 5, 2013 to Integral Molecular, expanding the company’s landscape of Lipoparticle intellectual property. Integral Molecular is the exclusive world-wide patent holder or licensee of all Lipoparticle patents, and licensed Lipoparticle technology is available only from Integral Molecular. Additional patents covering Lipoparticle technology are pending.
“Complex membrane proteins are exceptionally difficult to study, and there are currently no FDA approved antibody therapeutics against high-value targets such as GPCRs, ion channels and transporters,” said Dr. Benjamin Doranz, President of Integral Molecular. “Lipoparticles have become an established route for membrane protein antibody discovery, and our growing patent landscape strengthens our commitment to the discovery of these therapeutically important antibodies.”
